Latest Safety News

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

AFT Pharmaceuticals secures tentative FDA approval for Scomara cream to treat rare facial tumours but faces a US launch delay due to orphan drug exclusivity. The approval bolsters prospects in other markets where AFT expects competitive advantages.

Cadoux Ltd and the SAFELOOP consortium have surpassed key performance and recycling targets in lithium-ion battery development, marking a world-first in commercial-scale use of recycled active materials enhanced by Cadoux's premiumHPA®. This breakthrough advances the pathway to gigafactory production and strengthens Cadoux's position in the EV battery supply chain.

PYC Therapeutics reports durable retinal gene expression and visual improvements from its PYC-001 candidate in Autosomal Dominant Optic Atrophy, supporting longer dosing intervals and expansion into glaucoma research.

Tivan Limited has appointed Robert Gerrard as CEO (Australia), elevated Dr Ellin Lede to the Board, and named Brendon Nicol as CTO to sharpen its leadership as it moves towards key project milestones at Speewah and Molyhil.

Orezone Gold Corporation has resumed operations at its Quebec Casa Berardi mine following a brief wildfire-induced suspension, reaffirming its 2026 production guidance of up to 67,000 ounces while advancing maintenance work.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Yancoal's June quarter saw a 20% jump in attributable saleable coal production to 10.8 million tonnes, supported by rising realised coal prices and operational improvements. The company advances its strategic growth with the pending acquisition of an 80% stake in the Kestrel Coal Mine, while planning to close Ashton mine by early 2028.

Truscott Mining (ASX: TRM) is pressing ahead at its Tennant Creek projects, updating its flagship Westminster resource and confirming structural gold mineralisation from recent drilling. Expansion plans across North Tennant and Barkly projects underpin a disciplined, multi-year exploration strategy.

Podium Minerals has confirmed robust platinum group metals mineralisation extending to 500 metres depth at Parks Reef, reinforcing the project's scale and growth potential amid supportive market fundamentals.

Resources & Energy Group Limited (ASX:REZ) has formalised a joint venture with Rembrandt Mining to commence gold production at its Maranoa deposit, with Rembrandt funding all capital expenditure and REZ retaining full ownership and legal operator status.

Actinogen Medical’s phase 2 trial of Xanamem in major depressive disorder with cognitive impairment reveals meaningful antidepressant effects, published in the British Journal of Psychiatry. The drug was safe and well-tolerated but did not improve cognition.